
Conference Coverage
Latest News

Lebrikizumab Earns FDA Approval for Less Frequent, Every-8-Week Maintenance Dosing in AD

Journal Digest: June 10, 2026

Azithromycin Pulse Therapy Matches Doxycycline Efficacy for Acne with Fewer Adverse Effects

Dual-Action Microneedle Patch Shows Promise for Psoriasis in Preclinical Study

FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
Videos

Shorts










Podcasts
Dermatology Times Digital Edition







Continuing Medical Education
All News

The priority review pathway cuts the standard 300-day Canadian review timeline to approximately 180 days, reflecting Health Canada's assessment of serious unmet need in the EB population.

In clinical medicine and science, robust often fails because it lacks quantifiable meaning.

AI analysis of 187,016 menopausal women links hair loss severity to thyroid disease, gut symptoms, scalp inflammation, and genetics, supporting broader diagnostic workups beyond hormones.

As Epiduo goes OTC, offering once-daily adapalene+BPO for mild to moderate acne, Heather Woolery-Lloyd, MD, FAAD, gives advice on irritation, purging, and simplifying routines.

The June issue of Dermatology Times highlights the latest advances in skin cancer, psoriasis, atopic dermatitis, hidradenitis suppurativa, and emerging dermatology technologies.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Can daily supplements "clear skin from within", or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Plant-based oat oil and aloe moisturizer outperforms metronidazole in a 12-week trial, reducing rosacea redness and lesions safely without irritation.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Oral peptide drugs move beyond injections, bringing targeted psoriasis therapy like icotrokinra and reshaping dermatology’s treatment options.

Phase 1/2 data from RESET-Myositis, RESET-SSc, and RESET-SLE presented at EULAR 2026 show durable immunomodulator-free responses and a consistent safety profile across indications.

Medicus Pharma advances microneedle doxorubicin therapy to clear multiple Gorlin syndrome BCC lesions.

Experts recommend routine genital assessment as part of comprehensive skin exams rather than relying on patient-initiated reporting of this sensitive manifestation.

This review of the latest dermatological studies includes insights on PeakPASI in psoriasis severity, the future of digital derm lectures, negative pressure wound therapy, and more.

New IND pushes QRX003 toward first targeted therapy for peeling skin syndrome, with early pediatric results showing rapid healing and no safety issues.































